Clinical Trial Update: A Phase 3, Long-term, Extension Study of TVP-1012 (1 mg) in Early Parkinson's Disease Participants [Phase 3]

View source ↗

Summary

Phase 3 long-term extension study in early Parkinson's disease completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• TVP-1012

Snippet

Sponsor: Takeda | Conditions: Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2019-02-28